{"created":"2023-06-20T15:47:29.779081+00:00","id":2035,"links":{},"metadata":{"_buckets":{"deposit":"9f92489d-9cb3-4255-bdd8-f1727dd69cf8"},"_deposit":{"created_by":2,"id":"2035","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"2035"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00002035","sets":["1:11"]},"author_link":["5334","5336","5337","5339","5335","5338"],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-08-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"268","bibliographicPageStart":"263","bibliographicVolumeNumber":"32","bibliographic_titles":[{"bibliographic_title":"日本臨床免疫学会会誌"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"全身性エリテマトーデス（SLE）に対してステロイド，免疫抑制剤が使用され，一定の効果が得られている．しかし，効果不十分例や副作用のためこれらの治療が十分行えない症例が存在する．近年，ミコフェノール酸モフェチル（MMF）がSLEに有効であると報告され，新たな治療の選択肢として注目が集まっている．本研究では，ステロイド減量困難あるいは免疫抑制剤抵抗性を示した症例，または，副作用のためステロイドの継続投与が困難であった全身性エリテマトーデス16症例を対象とし，ミコフェノール酸モフェチル（MMF）の投与を行い臨床的効果，有害事象を評価した．16症例のうち，女性は13例（81%），男性は3例（19%）であり，平均年齢は44.4±9.2歳，平均罹病期間は12.5±6.9年であった．MMFとPSLの初期投与量はそれぞれ1.44±0.51 g，12.1±4.73 mgであり維持量はそれぞれ1.95±0.61 g，9.8±3.35 mgであった．MMFの平均投与期間は12.0±5.5ヶ月であった．臨床的改善は69%に認められ，臨床検査値では投与6ヶ月から有意なIgGの低下，アルブミン，補体価の上昇が認められた．有害事象は感染症が多かったが重篤なものはなかった．MMFは全身性エリテマトーデスに有効で，比較的に安全に使用できる可能性が示唆された．","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本臨床免疫学会"}]},"item_3_relation_28":{"attribute_name":"出版社DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2177/jsci.32.263","subitem_relation_type_select":"DOI"}}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2009 日本臨床免疫学会"},{"subitem_rights":"本文データは学協会の許諾に基づきJ-STAGEから複製したものである"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"09114300","subitem_source_identifier_type":"ISSN"}]},"item_3_source_id_20":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"13497413","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"鈴木, 大介"}],"nameIdentifiers":[{"nameIdentifier":"5334","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小川, 法良"}],"nameIdentifiers":[{"nameIdentifier":"5335","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"澤田, 仁"}],"nameIdentifiers":[{"nameIdentifier":"5336","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"木本, 理"}],"nameIdentifiers":[{"nameIdentifier":"5337","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"下山, 久美子"}],"nameIdentifiers":[{"nameIdentifier":"5338","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"林, 秀晴"}],"nameIdentifiers":[{"nameIdentifier":"5339","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"JJClinImmunol32_4-263.pdf","filesize":[{"value":"298.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JJClinImmunol32_4-263.pdf","url":"https://hama-med.repo.nii.ac.jp/record/2035/files/JJClinImmunol32_4-263.pdf"},"version_id":"c92b5ca0-19e7-4c4c-b735-0be633aa239b"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"mycophenolate mofetil","subitem_subject_scheme":"Other"},{"subitem_subject":"systemic lupus erythematosus","subitem_subject_scheme":"Other"},{"subitem_subject":"efficacy","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"ミコフェノール酸モフェチルの全身性エリテマトーデスにおける有用性の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ミコフェノール酸モフェチルの全身性エリテマトーデスにおける有用性の検討"}]},"item_type_id":"3","owner":"2","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"2035","relation_version_is_last":true,"title":["ミコフェノール酸モフェチルの全身性エリテマトーデスにおける有用性の検討"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-06-20T17:23:25.889925+00:00"}